We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

95 hedge funds and large institutions have $141M invested in Sciclone Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 41 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

151% more call options, than puts

Call options by funds: $409K | Put options by funds: $163K

0.86% more ownership

Funds ownership: 51.46% → 52.31% (+0.86%)

1% more capital inflows, than outflows

Capital inflows: $10.5M | Capital outflows: $10.4M

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

1% less funds holding

Funds holding: 96 → 95 (-1)

41% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 41

Holders
95
Holders Change
-1
Holders Change %
-1.04%
% of All Funds
2.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
24
Reduced
41
Closed
14
Calls
$409​K
Puts
$163​K
Net Calls
+$246​K
Net Calls Change
+$377​K

SCLN Hedge Fund Activity: Q2 2014 in Review

95 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals (SCLN) for Q2 2014, worth a combined $141M — up 15% from $122M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of SCLN and 13 opened new positions — a net loss of 1 holder — while 41 trimmed existing stakes and 24 added.

The largest buyer was Franklin Resources, adding an estimated $4.96M. The largest seller was BlackRock Institutional Trust, cutting an estimated $1.5M.

  • 95 institutional investors held Sciclone Pharmaceuticals (SCLN) as of Q2 2014, down from 96 in Q1 2014.
  • Funds reported $141M of Sciclone Pharmaceuticals stock for Q2 2014, up 15% quarter-over-quarter.
  • 13 funds opened new Sciclone Pharmaceuticals positions in Q2 2014 and 14 closed out, a net change of -1 holder.
  • The largest Sciclone Pharmaceuticals buyer in Q2 2014 was Franklin Resources, an estimated $4.96M added.
  • The largest Sciclone Pharmaceuticals seller in Q2 2014 was BlackRock Institutional Trust, an estimated $1.5M sold.

Based on aggregated 13F filings for Q2 2014.